EADO and ESMO Guidelines for Adjuvant Treatment in Stage II Melanoma

In this MEDtalk, Axel Hauschild, Professor of Dermatology at University Hospital Kiel, discusses upcoming European guidelines and current treatment strategies for stage II melanoma. The talk explores patient selection for adjuvant PD-1 therapy, the challenge of overtreatment, and how gene expression profiling and emerging combinations, including cemiplimab plus fianlimab and pembrolizumab with mRNA vaccination, may influence future standards of care.